| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 26, 2004
Accepted on November 15, 2004
Department of Pathology, University Health Network and University of Toronto; Department of Medicine, Mount Sinai Hospital and University of Toronto; The Freeman Centre for Endocrine Oncology and the Ontario Cancer Institute, Toronto, Ontario Canada
* To whom correspondence should be addressed. E-mail: sezzat{at}mtsinai.on.ca.
Several molecular abnormalities of potential therapeutic target value have been described in thyroid neoplastic transition. We report the expression of the fibroblast growth factor (FGF) receptor family (FGFR-1-4) in normal thyroid tissues, in human thyroid cancers of various types and behaviors, and in cell lines representative of the spectrum of differentiation of tumors derived from follicular epithelial cells. FGFR-2 was the only receptor consistently detected in normal human thyroid tissue, and its expression diminished in all thyroid cancers and carcinoma cell lines, suggesting that it may have a protective role. FGFR-1 and FGFR-3 were expressed in most well-differentiated tumor types. FGFR-4, however, was expressed predominantly in aggressive tumor types and in the most rapidly proliferative cell lines, indicating that it may promote the progression of these tumors. To specifically determine the function of FGFR-4 in thyroid carcinoma, gain- or loss-of-function studies were performed in cell lines representative of the spectrum of thyroid cancer behavior. Introduction of FGFR-4 resulted in enhanced cell proliferation, an effect that was more pronounced in cell lines derived from aggressive tumors than in those derived from more indolent neoplasms. Moreover, transduction of a dominant-negative FGFR (dnFGFR) attenuated cell proliferation in the aggressive poorly-differentiated cell lines with no appreciable effect in well-differentiated cells. Pharmacologic FGFR-4 tyrosine kinase inhibition resulted in significant proliferation arrest in an aggressive cell line endogenously expressing the receptor. Furthermore, systemic administration of the FGFR tyrosine kinase inhibitor PD173074 resulted in significant inhibition of follicular thyroid carcinoma-derived cell growth in xenografted SCID mice. These data indicate a role for FGFR-4 in human thyroid cancer cell progression and provide a rationale for FGFR manipulation as a potentially novel therapeutic approach.
This article has been cited by other articles:
 |
|
 |
|
  T. Kondo, X. Zhu, S. L. Asa, and S. Ezzat The Cancer/Testis Antigen Melanoma-Associated Antigen-A3/A6 Is a Novel Target of Fibroblast Growth Factor Receptor 2-IIIb through Histone H3 Modifications in Thyroid Cancer Clin. Cancer Res., August 15, 2007; 13(16): 4713 - 4720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kondo, L. Zheng, W. Liu, J. Kurebayashi, S. L. Asa, and S. Ezzat Epigenetically Controlled Fibroblast Growth Factor Receptor 2 Signaling Imposes on the RAS/BRAF/Mitogen-Activated Protein Kinase Pathway to Modulate Thyroid Cancer Progression Cancer Res., June 1, 2007; 67(11): 5461 - 5470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takeda, T. Arao, H. Yokote, T. Komatsu, K. Yanagihara, H. Sasaki, Y. Yamada, T. Tamura, K. Fukuoka, H. Kimura, et al. AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor Clin. Cancer Res., May 15, 2007; 13(10): 3051 - 3057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ezzat, L. Zheng, D. Winer, and S. L. Asa Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications Mol. Endocrinol., November 1, 2006; 20(11): 2965 - 2975. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
